ArticleJournal of nephrology2018
SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels.
Article in Journal of nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis.Journal of nephrology · 2019Trial
- A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.British journal of clinical pharmacology · 2019Trial
- The Relevance of Phytate for the Treatment of Chronic Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2024Review
- Gut microbial metabolites SCFAs and chronic kidney disease.Journal of translational medicine · 2024Review
- Pathophysiology and Clinical Impacts of Chronic Kidney Disease on Coronary Artery Calcification.Journal of cardiovascular development and disease · 2023Review
- Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease.Circulation research · 2023Review
- Review
- Phytate Intake, Health and Disease: "Let Thy Food Be Thy Medicine and Medicine Be Thy Food".Antioxidants (Basel, Switzerland) · 2023Review
- Research status of3 Biotech · 2021Review
- Setting the clock back: new hope for dialysis patients. Sodium thiosulphate and the regression of vascular calcifications.Journal of nephrology · 2021Article
- The Thermodynamics of Medial Vascular Calcification.Frontiers in cell and developmental biology · 2021Review
- Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification.Clinical kidney journal · 2021Article
- A novel assay to measure calcification propensity: from laboratory to humans.Scientific reports · 2020Article
- Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers.Nature communications · 2020Article
- Calciphylaxis: a conundrum for patients and nephrologists?Journal of nephrology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundCardiovascular calcification (CVC) is a major concern in hemodialysis (HD) and the loss of endogenous modulators of calcification seems involved in the process. Phytate is an endogenous crystallization inhibitor and its low molecular mass and high water solubility make it potentially dialyzable. SNF472 (the hexasodium salt of phytate) is being developed for the treatment of calciphylaxis and CVC in HD patients. We aimed to verify if phytate is lost during dialysis, and evaluate SNF472's behaviour during dialysis.
methodsDialyzability was assessed in vitro using online-hemodiafiltration and high-flux HD systems in blood and saline. SNF472 was infused for 20 min and quantified at different time points.
resultsPhytate completely dialyzed in 1 h at low concentrations (10 mg/l) but not when added at 30 or 66.67 mg/l SNF472. In bypass conditions, calcium was slightly chelated during SNF472 infusion but when the system was switched to dialysis mode the calcium in the bath compensated this chelation.
conclusionPhytate dialyses with a low clearance. The administration of SNF472 as an exogenous source of phytate allows to attain supra-physiological levels required for its potential therapeutic properties. As SNF472 is infused during the whole dialysis session, the low clearance would not affect the drug's systemic exposure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.